Biotech Immutep has scrapped clinical trials of its leading drug candidate, lung cancer treatment Efti, in a major blow for investors, including Phil King’s Regal Partners, which owns a 14 per cent ...

Swiss specialty drugmaker Santhera Pharmaceuticals today provides a trading update for the fiscal year 2025. The firm’s share dipped 3.2% to 16.50 francs following the announcement.

Life sciences as a growth driver in the portfolio With its life science activities, DAX giant BASF is positioning itself as a ...

After closing little changed for two straight days, stocks moved sharply lower over the course of the trading session on Thursday. With the steep losses on the day, the major ...